Altimmune Inc (ALT)

Currency in USD
5.55
-0.05(-0.89%)
Closed·
5.51-0.04(-0.68%)
·
ALT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
5.265.75
52 wk Range
2.907.73
Key Statistics
Prev. Close
5.6
Open
5.56
Day's Range
5.26-5.75
52 wk Range
2.9-7.73
Volume
4.8M
Average Volume (3m)
4.91M
1-Year Change
-16.4157%
Book Value / Share
2.1
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ALT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
17.67
Upside
+218.32%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales decline in the current year

Altimmune Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Altimmune Inc Company Profile

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Altimmune Inc SWOT Analysis


Pemvidutide Promise
Explore pemvidutide's potential in MASH and obesity treatment, with unprecedented liver fat reduction and significant weight loss results
Expanding Horizons
Delve into Altimmune's strategic expansion of pemvidutide applications to include alcohol use disorder and alcoholic liver disease
Clinical Milestones
Anticipate key clinical trial outcomes, including the Phase 2b IMPACT trial for MASH, with top-line data expected in Q2 2025
Market Potential
Analyst price targets range from $12 to $28, with projected peak U.S. sales exceeding $2.5 billion for MASH indication alone
Read full SWOT analysis

Altimmune Inc Earnings Call Summary for Q2/2025

  • Q2 2025 EPS of -$0.27 beats -$0.31 forecast, driving 5.62% stock rise to $3.57 in premarket trading
  • Total cash increased 40% to $183.1M; R&D expenses down to $17.2M from $21M YoY; net loss improved to $22.1M from $24.6M YoY
  • NASH treatment shows promising trial results; end-of-Phase II FDA meeting scheduled for Q4 2025
  • New Board Chairman Jerry Durso appointed; company raised $88M in equity and secured $100M debt facility
  • Advancing Phase II trials for AUD and ALD; 48-week NASH treatment data expected later this year
Last Updated: 2025-08-12, 09:30 a/m
Read Full Transcript

Compare ALT to Peers and Sector

Metrics to compare
ALT
Peers
Sector
Relationship
P/E Ratio
−8.3x−2.1x−0.6x
PEG Ratio
−0.240.310.00
Price/Book
3.7x2.4x2.6x
Price / LTM Sales
34,751.7x44.8x3.4x
Upside (Analyst Target)
257.1%155.8%44.9%
Fair Value Upside
Unlock6.3%6.3%Unlock

Analyst Ratings

8 Buy
1 Hold
1 Sell
Ratings:
10 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 17.67
(+218.32% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Barclays
Buy20.00+260.36%-New CoverageJan 28, 2026
Evercore ISI
Buy22.00+296.40%25.00MaintainJan 27, 2026
Citizens
Buy14.00+152.25%-MaintainNov 12, 2025
Citizens
Buy14.00+152.25%15.00MaintainNov 06, 2025
H.C. Wainwright
Buy12.00+116.22%-MaintainOct 20, 2025

Earnings

Latest Release
Nov 06, 2025
EPS / Forecast
-0.21 / -0.27
Revenue / Forecast
5.00K / 2.14K
EPS Revisions
Last 90 days

ALT Income Statement

People Also Watch

3.970
SLS
+5.31%
20.72
SRPT
+1.87%
3.90
NAMM
+5.98%
13.960
VTYX
+0.07%
6.630
BCRX
+0.61%

FAQ

What Is the Altimmune (ALT) Stock Price Today?

The Altimmune stock price today is 5.55

What Stock Exchange Does Altimmune Trade On?

Altimmune is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Altimmune?

The stock symbol for Altimmune is "ALT."

What Is the Altimmune Market Cap?

As of today, Altimmune market cap is 701.30M.

What Is Altimmune's Earnings Per Share (TTM)?

The Altimmune EPS (TTM) is -1.06.

When Is the Next Altimmune Earnings Date?

Altimmune will release its next earnings report on Mar 26, 2026.

From a Technical Analysis Perspective, Is ALT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Altimmune Stock Split?

Altimmune has split 2 times.

How Many Employees Does Altimmune Have?

Altimmune has 59 employees.

What is the current trading status of Altimmune (ALT)?

As of Feb 03, 2026, Altimmune (ALT) is trading at a price of 5.55, with a previous close of 5.60. The stock has fluctuated within a day range of 5.26 to 5.75, while its 52-week range spans from 2.90 to 7.73.

What Is Altimmune (ALT) Price Target According to Analysts?

The average 12-month price target for Altimmune is USD17.67, with a high estimate of USD28 and a low estimate of USD1. 8 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +218.32% Upside potential.

What Is the ALT Premarket Price?

ALT's last pre-market stock price is 5.58. The pre-market share volume is 32,160.00, and the stock has decreased by -0.02, or -0.36%.

What Is the ALT After Hours Price?

ALT's last after hours stock price is 5.51, the stock has decreased by -0.04, or -0.68%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.